Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00812383 · ClinicalTrials.gov registry record · Phase 2
Carotid With Bivalirudin Angioplasty
A Phase 2 study, sponsored by Medstar Health Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 299
- Enrollment target
NCT00812383 is a Phase 2 study that has completed, run by Medstar Health Research Institute. The registered enrollment target is 299 participants.
The verdict
NCT00812383, a Phase 2 study, has completed, sponsored by Medstar Health Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 299 participants
- Enrollment target
Study Summary
Single center randomized clinical trial, to evaluate the safety and efficacy of carotid artery stenting using the RX ACCULINK™ Carotid Stent System with RX ACCUNET™ Embolic Protection System or PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System using Angiomax (bivalirudin)versus heparin as the anticoagulant for treatment of occlusive carotid artery disease in low and high risk patient cohorts.
Interventions
- DEVICE RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2003-08 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00812383
The ClinicalTrials.gov registry entry for NCT00812383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System is the first listed.
NCT00812383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00812383 about?
NCT00812383 is a clinical study titled "Carotid With Bivalirudin Angioplasty". Single center randomized clinical trial, to evaluate the safety and efficacy of carotid artery stenting using the RX ACCULINK™ Carotid Stent System with RX ACCUNET™ Embolic Protection System or PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System using Angiomax (bivalirudin)versus hep...
What is the current status of trial NCT00812383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 299 participants. The study started on 2003-08. Estimated completion is 2019-12.
What interventions are being tested in trial NCT00812383?
The interventions under investigation include: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System (DEVICE).
Who is sponsoring clinical trial NCT00812383?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.